FIG. 1



NCI-H358
U87 MG
MIAPaCa-2
NCI-H1975
NCI-N87
Capan-1
HCC827
KYSE-520
TNO-155
HBI-2376
RMC-4550
Cisplatin
% Viability
Drug concentration (μM)

FIG. 2A



Tumor Volume
Tumor Volume (mm3)
3000
2000
1000
0
0
5
10
15
20
Days of treatment
Vehicle
Rat IgG2a Isotype control
Anti-PD1 10mpk
HBI-2376 10mpk
TNO-155 10mpk
RMC-4550 10mpk

FIG. 2B





% Body weight change
40
30
20
10
0
-10
5
10
15
20
Days of treatment
Vehicle
Rat IgG2a Isotype control
Anti-PD1 10mpk
HBI-2376 10mpk
TNO-155 10mpk
RMC-4550 10mpk

FIG. 3




G1: Vehicle
G2: Isotype Control
G3: Anti-PD1
G4: HBI-2376
G5: TNO-155
G6: RMC-4550

FIG. 4




G1: Vehicle
G2: Isotype Control
G3: Anti-PD1
G4: HBI-2376
G5: TNO-155
G6: RMC-4550

FIG. 5



G1: Vehicle
G2: Isotype Control
G3: Anti-PD1
G4: HBI-2376
G5: TNO-155
G6: RMC-4550

FIG. 6



G1: Vehicle
G2: Isotype Control
G3: Anti-PD1
G4: HBI-2376
G5: TNO-155
G6: RMC-4550

FIG. 7



CD4+
15
10
5
0
1
2
3
4
5
6
G1: Vehicle
G2: Isotype Control
G3: Anti-PD1
G4: HBI-2376
G5: TNO-155
G6: RMC-4550

FIG. 8



CD8+
10.0
7.5
5.0
2.5
0.0
1
2
3
4
5
6
G1: Vehicle
G2: Isotype Control
G3: Anti-PD1
G4: HBI-2376
G5: TNO-155
G6: RMC-4550

FIG. 9A





FIG. 9B



Absolute IC50 (μM)		
	HCC827-ER1	NCI-H1975 (L858R/T790M/C797S)
GH21001(TNO-155)	1.89	>10
GH21005(HBI-2376)	0.08	0.96
RMC-4550	1.23	>10
Osimertinib	2.8	2.43
Cisplatin	7.17	10.33

FIG. 10A




FIG. 10B




FIG. 11




FIG. 12A

(HCC827 CDX)




FIG. 12B

(HCC827 CDX)




FIG. 13A




FIG. 13B




FIG. 13C




FIG. 13D

(DUSP6)

qPCR




FIG. 13E

(10 day treatment at 10 mg/kg)





FIG. 13F

(10 day treatment at 10 mg/kg)






FIG. 13G




FIG. 14A




FIG. 14B



G1
G2
MIA PaCa-2
5028
5047
5060
5065
5066
5069
5074
5023
5061
5070
5076
5051
5063
5071
5072
DUSP6
β-actin
Group 1 Vehicle
Group 02 HBI-2376 10 mg/kg
Group 03 Osimertinib 5mg/kg
Group 04 RMC-4550 10 mg/kg
DUSP6/β-actin in HCC827-ER1 CDX tumors
Normalized DUSP6/β-actin
1.5
1.0
0.5
0.0
MIA PaCa-2
G1
G2

FIG. 15A




FIG. 15B

